Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212999 | 1.00 | HSD11B1 (0.64) | HSD11B1CYP3A4CYP2C9KCNH2CYP2C19 | |
| SCHEMBL3203281 | 1.00 | HSD11B1 (0.64) | HSD11B1CYP3A4CYP2C9KCNH2CYP2C19 | |
| SCHEMBL595384 | 0.94 | HSD11B1 (0.72) | HSD11B1CYP3A4CYP2C9KCNH2CYP2C19 | |
| SCHEMBL118735 | 0.94 | HSD11B1 (0.72) | HSD11B1CYP3A4CYP2C9KCNH2CYP2C19 | |
| SCHEMBL117180 | 0.94 | HSD11B1 (0.72) | HSD11B1CYP3A4CYP2C9KCNH2CYP2C19 | |
| SCHEMBL117181 | 0.94 | HSD11B1 (0.72) | HSD11B1CYP3A4CYP2C9KCNH2CYP2C19 | |
| SCHEMBL1025999 | 0.88 | HSD11B1 (0.60) | HSD11B1CYP3A4CYP2C9KCNH2CYP2C19 | |
| SCHEMBL1755342 | 0.85 | HSD11B1 (0.59) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13953371 | 0.85 | HSD11B1 (0.59) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL117338 | 0.85 | HSD11B1 (0.73) | HSD11B1CYP3A4CYP2C9KCNH2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202857-B2 | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202857-B2 | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100041637-A1 | 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041637-A1 | 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041637-A1 | 1,3-Oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885CYP3A4 202/4885CYP2C9 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.